Company / Cash & Equivalents
CytomX Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$12.7M
FY2025
5-year range
$12.7M / $205.5M
FY2021-FY2025
Trend
-66.7%
vs FY2024
Sector context
#204 of 207
Health Care
What the data says
Among 207 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 1% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $13M in FY2025 to $248M in FY2018.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -41.9%.
Declined from $17M to $13M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -59.7%
- 5-Year CAGR
- -41.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 207This company $12.7M Sector average $669.5M
▼
-98.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -41.9%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 66.7% year-over-year.
- Ranks #204 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.7M | -66.7% |
| FY2024 | $38.1M | +121.6% |
| FY2023 | $17.2M | -91.1% |
| FY2022 | $193.7M | -5.8% |
| FY2021 | $205.5M | +7.1% |
| FY2020 | $191.9M | +1.8% |
| FY2019 | $188.4M | -23.9% |
| FY2018 | $247.6M | +39.4% |
| FY2017 | $177.5M | +69.7% |
| FY2016 | $104.6M | +1102.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026